Article
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
Molecular cancer therapeutics - 1 Feb 2019
Fricke Stephanie L, Payne Susan N, Favreau Peter F, Kratz Jeremy D, Pasch Cheri A, Foley Tyler M, Yueh Alexander E, Van De Hey Dana R, Depke Mitchell G, Korkos Demetra P, Sha Gioia Chengcheng, DeStefanis Rebecca A, Clipson Linda, Burkard Mark E, Lemmon Kayla K, Parsons Benjamin M, Kenny Paraic A, Matkowskyj Kristina A, Newton Michael A, Skala Melissa C, Deming Dustin A
Abstract excerpt
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support this approach. Here we describe a cohort of patients treated with cancers possessing mutations activating the PI3K signaling cascade with minimal benefit to treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.